Pharvaris (PHVS) is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs and improve standard of care in bradykinin-mediated angioedema.
Pharvaris is a Dutch company with headquarters in Zug, Switzerland, and offices in Leiden, the Netherlands, and Lexington, Massachusetts.
Building on its legacy, scientific expertise, and core values, Pharvaris is harnessing established science to pioneer science for patient choice. The company’s aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks.
